TAKEDA PHARMS USA Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TAKEDA PHARMS USA, and what generic alternatives to TAKEDA PHARMS USA drugs are available?
TAKEDA PHARMS USA has forty approved drugs.
There are one hundred and six US patents protecting TAKEDA PHARMS USA drugs.
There are one thousand four hundred and thirty patent family members on TAKEDA PHARMS USA drugs in fifty-nine countries and one hundred and eighty-eight supplementary protection certificates in nineteen countries.
Summary for TAKEDA PHARMS USA
| International Patents: | 1430 |
| US Patents: | 106 |
| Tradenames: | 43 |
| Ingredients: | 33 |
| NDAs: | 40 |
Drugs and US Patents for TAKEDA PHARMS USA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | OSENI | alogliptin benzoate; pioglitazone hydrochloride | TABLET;ORAL | 022426-004 | Jan 25, 2013 | DISCN | Yes | No | 8,637,079 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Takeda Pharms Usa | VYVANSE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 021977-007 | Oct 30, 2014 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-003 | Sep 30, 2013 | DISCN | Yes | No | 9,278,096*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Takeda Pharms Usa | FOSRENOL | lanthanum carbonate | POWDER;ORAL | 204734-002 | Sep 24, 2014 | RX | Yes | Yes | 7,465,465 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-001 | Jan 30, 2009 | AB | RX | Yes | No | 9,011,926 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TAKEDA PHARMS USA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-001 | Jul 15, 1999 | 6,329,404 | ⤷ Subscribe |
| Takeda Pharms Usa | ACTOPLUS MET XR | metformin hydrochloride; pioglitazone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022024-001 | May 12, 2009 | 4,687,777 | ⤷ Subscribe |
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-002 | Jan 30, 2009 | 9,145,389 | ⤷ Subscribe |
| Takeda Pharms Usa | ACTOPLUS MET XR | metformin hydrochloride; pioglitazone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022024-002 | May 12, 2009 | 9,060,941 | ⤷ Subscribe |
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-002 | Mar 27, 2012 | 7,919,118 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TAKEDA PHARMS USA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 3.5 mg/vial | ➤ Subscribe | 2008-11-20 |
| ➤ Subscribe | Chewable Tablet | 500 mg, 750 mg and 1000 mg | ➤ Subscribe | 2008-10-27 |
| ➤ Subscribe | Delayed-release Tablets | 1.2 g | ➤ Subscribe | 2009-12-16 |
| ➤ Subscribe | Extended-release Tablets | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2009-12-29 |
| ➤ Subscribe | Tablets | 0.6 mg | ➤ Subscribe | 2011-12-23 |
| ➤ Subscribe | Delayed-release Orally Disinte | 15 mg and 30 mg | ➤ Subscribe | 2006-12-27 |
| ➤ Subscribe | Tablets | 12.5 mg/500 mg and 12.5 mg/1000 mg | ➤ Subscribe | 2017-01-25 |
| ➤ Subscribe | Delayed-release Capsule | 30 mg | ➤ Subscribe | 2010-11-30 |
| ➤ Subscribe | Tablets | 8 mg | ➤ Subscribe | 2009-07-22 |
| ➤ Subscribe | Extended-release Capsules | 37.5 mg and50 mg | ➤ Subscribe | 2017-08-03 |
| ➤ Subscribe | Tablets | 40 mg and 80 mg | ➤ Subscribe | 2013-02-13 |
| ➤ Subscribe | Capsules | 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg | ➤ Subscribe | 2011-02-23 |
| ➤ Subscribe | Injection | 10 mg/mL | ➤ Subscribe | 2015-08-25 |
| ➤ Subscribe | Oral Powder | 750 mg and 1000 mg | ➤ Subscribe | 2015-11-25 |
| ➤ Subscribe | Extended-release Tablets | 15 mg/1000 mg and 30 mg/1000 mg | ➤ Subscribe | 2011-09-23 |
| ➤ Subscribe | Tablets | 15 mg/500 mg and 15 mg/850 mg | ➤ Subscribe | 2008-03-06 |
| ➤ Subscribe | Delayed-release Pellets/Capsul | 15 mg and 30 mg | ➤ Subscribe | 2005-12-05 |
| ➤ Subscribe | Tablets | 30 mg/2 mg and 30 mg/4 mg | ➤ Subscribe | 2009-12-22 |
| ➤ Subscribe | Capsule | 60 mg | ➤ Subscribe | 2010-08-25 |
| ➤ Subscribe | Tablets | 6.25 mg, 12.5 mg and 25 mg | ➤ Subscribe | 2017-01-25 |
| ➤ Subscribe | Extended-release Capsules | 100 mg and 200 mg | ➤ Subscribe | 2006-02-02 |
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mgand 20 mg | ➤ Subscribe | 2017-10-02 |
| ➤ Subscribe | Extended-release Capsules | 12.5 mg and 25 mg | ➤ Subscribe | 2017-08-07 |
International Patents for TAKEDA PHARMS USA Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2536959 | ⤷ Subscribe |
| Canada | 2695082 | ⤷ Subscribe |
| Japan | 2010517937 | ⤷ Subscribe |
| Hungary | 230189 | ⤷ Subscribe |
| Australia | 2003272098 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for TAKEDA PHARMS USA Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1586571 | 2014/012 | Ireland | ⤷ Subscribe | PRODUCT NAME: ALOGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/844/001-027 20130919 |
| 1586571 | 252 5006-2014 | Slovakia | ⤷ Subscribe | PRODUCT NAME: ALOGLIPTIN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/13/844/001 - EU/1/13/844/027 20130923 |
| 0906338 | 2013/006 | Ireland | ⤷ Subscribe | PRODUCT NAME: TEDUGLUTIDE; REGISTRATION NO/DATE: EU/1/12/787/001 20120830 |
| 1644019 | 2020C/543 | Belgium | ⤷ Subscribe | PRODUCT NAME: LISDEXAMFETAMINE, OPTIONEEL IN DE VORM VAN EEN MESYLAAT- OF HYDROCHLORIDE-ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE562026, BE562035, BE562044, BE562053, BE562062, BE562071 20200520 |
| 2300013 | 122019000046 | Germany | ⤷ Subscribe | PRODUCT NAME: BRIGATINIB, ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1264 20181122 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
